Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds

Pediatric Infectious Disease Journal

Volumn 20, Issue 4, 2001, Pages 427-433

  Pichichero, Michael E ^a,f   Anderson, Edwin L ^b   Rennels, Margaret B ^c   Edwards, Kathryn M ^d   England, Janet A ^e  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c University of Maryland School of Medicine Center for Vaccine Development   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Diphtheria; Pertussis; Tetanus; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; BACTERIUM ANTIBODY; BORDETELLA VIRULENCE FACTOR; DIPHTHERIA TOXIN; TETANUS TOXIN;

ANTIBODY TITER; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; NORMAL HUMAN; PERTUSSIS; PRIORITY JOURNAL; SEROLOGY; TETANUS; VACCINATION; BIOSYNTHESIS; IMMUNOLOGY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; DIPHTHERIA TOXIN; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HUMANS; IMMUNIZATION, SECONDARY; RANDOMIZED CONTROLLED TRIALS; TETANUS TOXIN; VIRULENCE FACTORS, BORDETELLA;

EID: 0034744959     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200104000-00011     Document Type: Article

References (38)

1. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis
2. Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants
3. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines
4. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis
5. Cell-mediated and antibody responses-Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines
6. Pertussis: Current concepts of pathogenesis and prevention
7. The acellular pertussis vaccine trials: An interpretation
8. Pertussis vaccination: Acellular pertussis vaccine for the fourth and fifth doses of the DTP series: Update to supplementary ACIP statement. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
9. Comparison of thirteen acellular pertussis vaccines: Overview and serologic response
10. A comparison of 12 acellular pertussis vaccines with one whole cell pertussis vaccine when given as a fourth dose in 15 to 20-month-old children
11. Safety and immunogenicity of 6 DT acellular pertussis vaccines with one whole cell pertussis (DTwP) vaccine given as a fifth dose in 4 to 6-year-old children
12. Estimation of Corynebacterium diphtheriae antitoxin in human sera: A comparison of an enzyme-linked immunosorbent assay with the toxin neutralization test
13. Simultaneous administration of measles-mumps- rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines
14. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera
15. Methodology and evaluation of the serologic assays employed in a multicenter trial of acellular pertussis vaccines
16. Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model
17. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses
18. Titers of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis
19. Circulating antitoxin at the onset of diphtheria in 425 patients
20. Immunogenicity of tetanus-diphtheria toxoids (Td) among Ukrainian adults: Implications for diphtheria control in the Newly Independent States of the Former Soviet Union
21. Risk of diphtheria among schoolchildren in the Russian Federation in relation to time since last vaccination
22. The prophylactic dose of homologous tetanus antitoxin
23. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines
24. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis
25. A toxoid vaccine for pertussis as well as diphtheria? Lessons to be learned
26. Parapertussis infection followed by pertussis infection
27. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis
28. Serologic correlates in whooping cough
29. Collaborative study for the evaluation of enzyme-linked immunosorbent assays used to measure human antibodies to Bordetella pertussis antigens
30. Susceptibility to diphtheria among elderly persons: Immunization by the intracutaneous administration of toxoid
31. Diphtheria: Changing patterns in the developing world and the industrialized would
32. The immunological basis for immunization
33. Antibody synthesis by bone marrow cells in vitro following primary and booster tetanus toxoid immunization in humans
34. Kinetics of booster responses to Haemophilus influenzae type b conjugate after combined diphtheria-tetanus-acellular pertussis-Haemophilus influenzae type b vaccination in infants